Indicated in adolescents (12-17 years old)
with moderate-to-severe atopic dermatitis

DUPIXENT® (dupilumab injection) is indicated for the treatment of patients aged 6 years and older with moderate-to-severe atopic dermatitis whose disease is not adequately controlled with topical prescription therapies or when those therapies are not advisable.
DUPIXENT® can be used with or without topical corticosteroids.


† The safety of DUPIXENT® was assessed in a study of 250 patients 12 to 17 years of age with moderate-to-severe AD (AD-1526) at Week 16 and the long-term safety of DUPIXENT® was assessed in an open-label extension study in patients 12 to 17 years of age with moderate-to-severe AD (AD-1434) through Week 52.1



DUPIXENT®, Sanofi and Freedom logos are trademarks of Sanofi, used under license by sanofi-aventis Canada Inc.
REGENERON® is a trademark of Regeneron Pharmaceuticals, Inc. All rights reserved.
© 2023 sanofi-aventis Canada Inc. All rights reserved.

MAT-CA-2300298
Last updated: 06/2023

paab logo